07.07.2022 • NewsThyssenkruppcaustic soda

Thyssenkrupp Nucera Wins India Caustic Soda Project

German technology company Thyssenkrupp Nucera has won a contract to expand a caustic soda plant for India’s Kutch Chemical Industries. The contract’s value is in the low double-digit million-euro range.

Thyssenkrupp Nucera will grant a license and supply proprietary equipment to expand the plant, which is located in Padana, Gujarat, and comprises five electrolyzers that are based on the German firm’s bipolar membrane single element technology.

The project – Thyssenkrupp Nucera’s second for Kutch – will more than double current capacity, providing an additional 670 t/d. Completion and commissioning are scheduled for some time in 2023.

Kutch said the project will strengthen its market position and meet growing regional demand for basic chemicals, as well as its own rising demand. Caustic soda is used in a large number of end-products such as detergents, soaps and disinfectants, as well as processing raw aluminum.

Part of the Goyal Group of Industries, Kutch produces specialty chemicals that include intermediates for pharmaceuticals, agrochemicals and dyes, and the company touts itself as being “highly experienced” in chlorination, nitration, sulfonation, hydrogenation, ethoxylation and ammonolysis processes.

Author: Elaine Burridge, Freelance Journalist

© Thyssenkrupp Nucera
© Thyssenkrupp Nucera

Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.